INBX
NASDAQ · Biotechnology
Inhibrx Biosciences Inc
$88.66
+2.87 (+3.35%)
Open$86.78
Previous Close$85.79
Day High$89.28
Day Low$80.42
52W High$155.29
52W Low$20.55
Volume—
Avg Volume179.8K
Market Cap1.26B
P/E Ratio—
EPS$-8.39
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
-79.6% upside
Current
$88.66
$88.66
Target
$18.13
$18.13
$12.39
$18.13 avg
$27.56
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.29M | 1.53M | 384.43M |
| Net Income | -138,725,094 | -148,598,648 | -115,444,062 |
| Profit Margin | -10,773.5% | -10,234.8% | -30.0% |
| EBITDA | -131,283,696 | -148,440,265 | -155,644,267 |
| Free Cash Flow | — | — | -85,235,104 |
| Rev Growth | -16.0% | -16.0% | -5.8% |
| Debt/Equity | 12.58 | 12.58 | 0.10 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |